08. June 2020 | 11:30 CET
Aurora, Bayer, XPhyto - scalable growth markets with potential
Health is the most precious good in the life of a human being. The preservation and improvement of the quality of life is a large business area. Investors around the globe have the opportunity to participate in many different areas of research and development of products and therapies. The development of new markets and preparations usually requires a lot of risk capital before the fruits can be harvested. At the latest when a scalable solution has been found to improve people's lives, then the value of the company increases.
time to read:
ISIN: CA98421R1055 , CA05156X8843 , DE000BAY0017
Patches to treat diseases
The Canadian company XPhyto Therapeutics Corp. announced this morning that its wholly owned German subsidiary, Vektor Pharma TF GmbH, has completed the formula for its novel transdermal delivery system for the neurological drug Rotigotine. Vektor is now proceeding with the process implementation for the production of Rotigotine patches for human clinical trials.
The active ingredient Rotigotine is a generic and off-patent drug and is used for the treatment of Parkinson's disease and restless legs syndrome in Europe and the United States. The global market for Rotigotine patches was worth approximately CAD 250 million to CAD 500 million in 2019.
Results expected in 2020
"We are extremely pleased with the TDS development results thus far. It appears that our goal of optimizing the dosage form efficiency, to reduce the amount of drug required in each patch, and improving overall patch adhesion to the patient's skin has been achieved," said Prof. Dr. Thomas Beckert, founder and managing director of Vektor.
Once process implementation is complete, clinical sample manufacturing and analytical work will commence in Vektor's EU GMP laboratory and manufacturing facility based in Baden-Württemberg, Germany. Human pilot studies in Europe are scheduled for Q3 2020 with results expected in Q4 2020, according to today's announcement.
Newcomers with potential
The market value of XPhyto at the current share price level of EUR 2.11 is approximately EUR 116 million. Compared to other companies dealing with the topic of health the value is still low and at the same time expresses the potential. Aurora Cannabis has a market value of EUR 1.39 billion at a share price of EUR 12.57. With a market capitalisation of EUR 64.99 billion and a share price of EUR 66.62, the pharmaceutical giant Bayer is a heavyweight.
Usually every company starts small and XPhyto is positioned in promising and scalable growth markets with its German subsidiaries Bunker Pflanzenextrakte GmbH and Vektor Pharma TF GmbH.